Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aspen Aerogels (ASPN) Current Deferred Revenue (2016 - 2025)

Aspen Aerogels' Current Deferred Revenue history spans 13 years, with the latest figure at $1.3 million for Q4 2025.

  • For the quarter ending Q4 2025, Current Deferred Revenue fell 42.75% year-over-year to $1.3 million, compared with a TTM value of $1.3 million through Dec 2025, down 42.75%, and an annual FY2025 reading of $1.3 million, down 42.75% over the prior year.
  • Current Deferred Revenue for Q4 2025 was $1.3 million at Aspen Aerogels, up from $824000.0 in the prior quarter.
  • The five-year high for Current Deferred Revenue was $11.3 million in Q3 2021, with the low at $624000.0 in Q2 2025.
  • Average Current Deferred Revenue over 5 years is $3.5 million, with a median of $2.4 million recorded in 2022.
  • Year-over-year, Current Deferred Revenue crashed 85.84% in 2021 and then surged 230.89% in 2023.
  • Tracing ASPN's Current Deferred Revenue over 5 years: stood at $11.0 million in 2021, then tumbled by 47.09% to $5.8 million in 2022, then plummeted by 60.38% to $2.3 million in 2023, then decreased by 5.05% to $2.2 million in 2024, then tumbled by 42.75% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for ASPN's Current Deferred Revenue are $1.3 million (Q4 2025), $824000.0 (Q3 2025), and $624000.0 (Q2 2025).